Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.

There is currently no population screening programme for prostate cancer in the UK, a position that is reflected internationally (e.g. the USA Preventative Services Taskforce recommends shared decision-making [1]). Second, the CAP trial observed that PSA screening misses lethal cancers: 36% (68/188) of men who died from prostate cancer attended the PSA-screening clinic, highlighting that clinically significant prostate cancer is not uncommon among men with low PSA levels. [Extracted from the article]